Elisabeth Rouits

Title: Elisabeth Rouits: Innovator in Cancer Treatment

Introduction

Elisabeth Rouits is a prominent inventor based in Crissier, Switzerland. She has made significant contributions to the field of cancer treatment through her innovative research and development of immunoconjugates. Her work focuses on improving therapeutic outcomes for cancer patients while minimizing adverse effects.

Latest Patents

Elisabeth holds a patent for a method aimed at treating cancer in human patients. The patent, titled "Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens," outlines methods of administering immunoconjugates that bind to CD37. This approach includes the administration of an anti-CD37 immunoconjugate, potentially in combination with anti-CD20 therapy, to patients in need, particularly those suffering from cancer. The method emphasizes achieving a therapeutically effective dosing regimen that results in minimal adverse effects. She has 1 patent to her name.

Career Highlights

Elisabeth Rouits is associated with Debiopharm International, S.A., a company known for its commitment to advancing cancer therapies. Her role at the company has allowed her to focus on innovative solutions that address critical needs in cancer treatment.

Collaborations

Elisabeth collaborates with Nigel Mccracken, leveraging their combined expertise to enhance the development of effective cancer therapies.

Conclusion

Elisabeth Rouits stands out as an influential inventor in the realm of cancer treatment, with her innovative methods promising to improve patient outcomes. Her dedication to research and collaboration continues to drive advancements in the field.